Amwins Global Risks has announced its partnership with Blood Cancer UK in a fundraiser that is expected to bring in up to £100,000 in funds over the next two years for cancer research and awareness. The partnership aims to raise awareness of blood cancer, the third most prevalent type of cancer in the UK.
According to a news release, multiple myeloma is a type of blood cancer that affects more than 5,000 people in the UK every year. One of those affected is Matthew Wilson, a leader in the insurance industry. He was diagnosed with the condition in 2021.
The money to be raised with the partnership will go toward the Matthew Wilson Multiple Myeloma Fund set up by Matthew and his family with Blood Cancer UK.
The fund has already supported the educational pursuit of two clinical research fellows, leading to their PhD titles. One of the fellows is focused on understanding the key molecules that help myeloma cells grow in number and thrive. The other fellow’s focus will be on understanding the causes of myeloma so new screening tools and drugs can be developed.
"I'm thrilled that the money from Amwins will go towards life-saving blood cancer research, so we can bring forward the day we find a cure for multiple myeloma, the type of blood cancer I was diagnosed with two years ago. Hopefully, together with all those at Amwins, we can make a real difference to people's lives,” said Wilson.
Rachel Calderon, deputy director of fundraising at Blood Cancer UK has welcomed the announcement. "While 40,000 people are diagnosed with blood cancer every year, it remains a hidden cancer. This means that, too often, people with blood cancer don't feel that others understand what we're going through or treat the condition as seriously as they should,” she said.
"We're delighted to join forces with Amwins to improve the lives of those affected by blood cancer. With their support we can accelerate our efforts to find new treatments for the blood cancer through establishing pioneering research leaders in myeloma. And raising awareness about the challenges faced by those with blood cancer will be critical to achieving this."
“Our collaboration with Blood Cancer UK aligns perfectly with our values and commitment to creating positive change,” said Nate Mathis, CEO of Amwins Global Risks. “We are so proud to be supporting the Matthew Wilson Multiple Myeloma Fund and Blood Cancer UK in their work to beat blood cancer.”
Have thoughts about this story? Let us know in the comments below.
